Bavarian Nordic A/S (OTCMKTS:BVNRY) Short Interest Down 73.2% in September

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totalling 2,200 shares, a drop of 73.2% from the August 31st total of 8,200 shares. Based on an average daily trading volume, of 118,000 shares, the days-to-cover ratio is currently 0.0 days.

Bavarian Nordic A/S Trading Down 2.4 %

OTCMKTS:BVNRY traded down $0.29 during mid-day trading on Wednesday, reaching $11.55. 38,714 shares of the stock were exchanged, compared to its average volume of 52,577. The business has a fifty day moving average price of $11.18 and a 200 day moving average price of $9.07. Bavarian Nordic A/S has a 1-year low of $5.95 and a 1-year high of $14.60. The firm has a market capitalization of $2.71 billion, a PE ratio of 14.99 and a beta of 1.70.

Bavarian Nordic A/S (OTCMKTS:BVNRY) last posted its quarterly earnings data on Thursday, August 22nd. The company reported $0.16 earnings per share for the quarter. Bavarian Nordic A/S had a net margin of 11.50% and a return on equity of 12.50%. The company had revenue of $205.99 million during the quarter. On average, sell-side analysts forecast that Bavarian Nordic A/S will post 0.57 earnings per share for the current year.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.